CoA Therapeutics unveils timeline on path to PKAN clinical trial

CoA Therapeutics, a BridgeBio affiliate, has completed a Phase I healthy volunteer study evaluating the safety, tolerability and drug-like properties of BBP-671. We will present healthy volunteer data from the Phase I study at the 4th Pan-American Congress on Parkinson's Disease and Movement Disorders, which will be held May 26-28, 2022.
In 2022, we are focusing on two activities: improving our formulation for PKAN patients and gathering feedback on our clinical trial design from regulatory authorities in the EU and the US. Based on your feedback from the survey, we are developing small tablets for use in our clinical trial. We are working with the EMA and, later in the year, the FDA to seek their advice on our clinical plans. These activities take time and we hope to open trial sites in the U.S. and Europe in mid-2023.
We know that time is of the essence for individuals with PKAN and their families, and we are doing our best to move forward as quickly as possible.

Source: 03/13/2022, communication from CoA Therapeutics to the PKAN community.